Smallpox Vaccine

Summary

Smallpox Vaccine (CHEMBL2108688) is a phase-3 clinical-stage vaccine component; indicated across 3 conditions including smallpox and hiv infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Vaccine component
• Indications: 3 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108688
Name	Smallpox Vaccine
Type	Vaccine component
Max phase	3

Also known as: Smallpox vaccine, SMALLPOX VACCINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
smallpox	3	MONDO:0004651	MONDO:0004651
HIV infectious disease	1	MONDO:0005109	EFO:0000764

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	2
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00607243	PHASE2/PHASE3	COMPLETED	Safety and Efficacy of CJ-50300 in Healthy Volunteers
NCT01056770	PHASE3	COMPLETED	Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers
NCT01317238	PHASE3	COMPLETED	Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
NCT00258947	PHASE2	COMPLETED	Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
NCT00000767	PHASE1	COMPLETED	A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
NCT00002261	PHASE1	COMPLETED	A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).